Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (noting the input metadata reference to Serina Therapeutics appears to be a discrepancy, as the filing explicitly names AgeX) on August 14, 2019. The registrant is a Delaware corporation with principal executive offices in Alameda, California, and its common stock trades on the NYSE American under the symbol AGE. The filing serves to announce financial results for the three and six months ended June 30, 2019.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the financial results are detailed in a press release attached as Exhibit 99.1, which is incorporated by reference. Consequently, no specific financial metrics can be extracted from the provided text.
Material Changes
The filing does not provide specific data regarding material changes versus prior comparable periods. It directs readers to the attached press release (Exhibit 99.1) for the announcement of results for the three and six months ended June 30, 2019.
Guidance, Outlook, and Risks
The document includes a standard Forward-Looking Statements disclaimer. It warns that statements containing words such as "may," "will," "believes," "plans," "intends," "anticipates," "expects," and "estimates" are forward-looking and subject to risks. The registrant disclaims any obligation to update these statements. Specific risks are referenced as being contained in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors."
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 press release, as they are not present in the 8-K text.
- Confirm the company name discrepancy between the input metadata ("Serina Therapeutics") and the filing ("AgeX Therapeutics, Inc.").
- Review the "Risk Factors" section in the most recent Form 10-K or 10-Q for detailed contingencies affecting the forward-looking statements.
- Check the status of the company's emerging growth company election and its impact on financial reporting standards.